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TWEAK and Fn14 are members of the TNF ligand and receptor superfamilies. Upon observation that 
xenopus Fn14 cross reacts with human TWEAK, despite its relatively low sequence homology to human 
Fn14, we set out to examine the conservation in tertiary fold and binding interfaces between the two 
species. Our results, combining NMR solution structure determination, binding assays, extensive site-
directed mutagenesis and molecular modeling, reveal that in addition to the known and previously 
characterized β-hairpin motif, the helix-loop-helix motif brings an essential contribution to the 
receptor/ligand binding interface. We further discuss the insight provided by the structural analyses on 






TNF (tumor necrosis factor) family ligands and their receptors, to which TWEAK (TNF like weak 
inducer of apoptosis) and its receptor Fn14 (fibroblast growth factor inducible immediate-early response 
protein 14) belong, regulate a wide range of biological processes including inflammation, lymphocyte 
survival and activation, as well as tissue repair and remodeling [1, 2]. Although the TWEAK-Fn14 
pathway does not seem to play any obligatory role in tissue development and homeostasis, growing 
evidence indicates that TWEAK-mediated Fn14 activation constitutes an evolutionarily highly conserved 
[3-5] physiological response to injury by facilitating tissue regeneration and repair [6, 7].  However, 
dysregulation of the TWEAK-Fn14 pathway under pathological conditions can contribute to 
amplification of an excessive inflammatory response, to pathogenic angiogenesis and  tissue remodeling, 
to inhibition of endogenous repair mechanisms, [8] and has been related to aspects of tumor growth and 
metastasis [9].  
Fn14 along with BCMA, BAFFR and TACI is one of the smallest TNF receptors. It contains just a single 
extracellular cysteine rich domain (CRD), and two nested disulfide bridges, a disulfide bond pattern 
different from that of BCMA and TACI (Fig. 1) [10]. In the current study, we  relate the solution 
conformations and  ligand binding affinities of the soluble ectodomains of human and  xenopus Fn14. 
Despite considerable divergence in their primary sequences, human and xenopus Fn14 adopt a nearly 
identical overall fold consistent with the observation that both can bind to human TWEAK. The 
conserved structural motifs, coupled with site-directed mutagenesis of both Fn14 and TWEAK allow  us 
to define the interaction site and to model the interface of the TWEAK/Fn14 complex using the available 
structures of other TNFRs in complex with their ligands [11-13] and the newly determined solution 
structure of BCMA.  
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Results and discussion 
Evolutionary conservation of TWEAK-Fn14 interactions  
Human and xenopus Fn14 (referred to as hFn14 and xeFn14) share only 37% sequence identity overall 
and 40% in the extracellular domain [14], but share several common features (Fig. 1), including a single 
extracellular CRD with six identically-spaced cysteine residues that are separated by short stretches of 
homologous amino acids. To test the role of the conserved residues in interacting with TWEAK we 
measured the binding of human or xenopus Fn14 to human TWEAK by fluorescence-activated cell 
sorting (FACS), enzyme-linked immunosorbent assay (ELISA) and surface plasmon resonance (SPR).  
Figure 2A shows FACS analysis in which we transfected full-length hFn14 or xeFn14 into 293 T cells 
and measured the binding of Fc-hTWEAK. Similarly, figure 2B shows ELISA results with Fc-hTWEAK 
titrated on human or xenopus Fn14 coated plates. We observed comparable binding to both species with 
an EC50 of 0.3 nM for Fc-hTWEAK binding to each receptor. The values are in agreement with what 
recently reported for a conjugated form of human TWEAK binding to hFn14 in human HT1080 and 
HT29 cells [15]. The high affinity detected for the xeFn14/hTWEAK interaction prompted us to measure 
the true, monovalent affinity of human and xenopus Fn14 for human TWEAK by SPR. Figure 2, panels C 
and D, shows the results of the equilibrium binding of monomeric xenopus or human Fn14 respectively to 
hTWEAK measured by SPR. hFn14 binds to hTWEAK with a KD = 65 nM (Fig. 2D) while xeFn14 binds 
to hTWEAK with a KD = 1.3 µM (Fig. 2C);  a 20-fold lower affinity than hFn14. This difference, which 
cannot be detected in avidity prone, multivalent-interaction assay formats [16], becomes apparent only 
when the single-site binding affinity is measured. Importantly, hTWEAK induced similarly robust NF-κB 
activation when co-transfected with either hFn14 or xeFn14 in 293T cells, indicating that the observed 
interaction with xeFn14 can yield functional signals (Fig. 2E). Taken together,  these data strongly 
suggests that endogenous interactions between TWEAK and Fn14 were by and large highly conserved 
during evolution.  
Solution structure of hFn14 and xeFn14 extracellular domains  
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To understand the structural basis underlying the high level of cross-species conservation of TWEAK - 
Fn14 interactions, we determined the structure of the extracellular ligand-binding domain of both hFn14 
and xeFn14 by NMR (Fig. 3A and B). The solution structure we obtained for hFn14 is in agreement with 
the published structure [17], with average pairwise rmsds in the structured regions of 0.62 and 0.47 Å 
(family of 20 structures vs. PDB code 2RPJ structure 1) and same tertiary arrangement.  hFn14 and 
xeFn14 share strong similarity in the NMR spectral pattern (chemical shifts and NOEs, Fig. S1), which 
translates to highly similar secondary and tertiary structures (rmsd 1.0 Å over secondary structure regions: 
residues 40-52, 61-64, backbone atoms, Fig. 3B; numbering as in hFn14).  The disulfide pattern of hFn14 
was determined using tandem mass spectrometry[10], and was further confirmed by NMR for both hFn14 
and xeFn14. Both proteins adopt a nested pattern in the two most C-terminal disulfide bonds, in contrast 
to the intercalated pattern observed in BCMA and TACI_d2, the two TNFR superfamily members 
previously thought to be most closely-related to Fn14 (Fig. 1B, 3A and 3C). The highly ordered β-hairpin 
domains (rmsd 0.24 Å and 0.20Å respectively, for each ensemble of 20 structures of hFn14 and xeFn14), 
converge to an rmsd of 0.56 Å. This area of the molecule has been previously reported to provide the 
majority of the interaction interface with the ligand for BCMA and BAFFR, and to be essential for 
binding in TACI and multi-domain TNF receptors (TNFR1, DR5) [18, 19].  
The relative arrangement of the C-terminal lobe of Fn14 proteins (helix1, residues 52-55, loop and helix2, 
residues 62-69) and the N-terminal β-hairpin is well defined by a number of long range NOEs radiating 
from the central aromatic residue Phe63/xPhe54 (for simplicity the first residue refers to hFn14 and the “x” 
residue to the correspondent in xeFn14; NOEs to Ser41/xAla32, Trp42/xTyr33, Ser43/xSer34, Met50/xMet41). In 
the case of xeFn14, long-range contacts between the two acidic residues xAsp53 and xAsp36 can also be 
clearly observed. To quantitatively evaluate NOEs and their impact on the final structures we utilized the 
program QUEEN [20]. The average information, Iave, of long range restraints connecting residues in the 
loop (Phe63, Gly66, Cys67; xPhe54, xAsn57, xCys58) to residues in N-terminal region (Ser41, Ser43 and  
xArg31- xSer34) is 32% and 35%  respectively of the total structural information,  indicating a dominant 
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role in the structure. NOEs in the helix2 region have a higher contribution in the dataset for hFn14 than 
for xeFn14 (a better chemical shift dispersion is observed). Correspondingly helix2 in the human protein 
is better defined and folds into a more compact coil (Fig. 3B). 
The observed structures closely resemble that of TACI_d2 (rmsd 0.52 Å between residues 40-50 of 
hFn14 and residues 77-87 of TACI_d2, lowest NOE violation structure, PDB code 1XUT) (Fig. 4A and 
C).  
Solution structure of BCMA 
The relative orientations of the N- and C-terminal lobes of Fn14 determined by NMR is strikingly 
different from those of TACI_d2 and especially BCMA as determined by crystallography [12, 13] (Fig. 
4). We confirmed that the solution structure of BCMA is highly similar to the crystal structures of BCMA 
determined previously in complex with BAFF or APRIL [12, 21]; the backbone rmsd over the ordered 
regions is 1.06 Å (lowest NOE violation structure vs. PDB code 1OQD). A similar analysis of the NMR 
restraints (QUEEN) indicates that the relative orientation of the N-and C-terminal lobes is well 
characterized by long range NOEs which constitute about 19% of the total structural information (sum of 
Iave), involving residues homologous to what observed for Fn14 (Pro34, Thr36, Tyr40, Cys41 to Asn11, Tyr13, 
Phe14). 
Tertiary fold and binding epitopes for single CRD TNFRs  
Overall, the fold of Fn14 is similar to those of BCMA, TACI_d2 and partially BAFFR, with the most 
striking similarity in the β-hairpin. The conserved DXL motif, located at the tip of the β-hairpin and 
essential for ligand binding [11, 12] is replaced in Fn14 by an SXDL sequence that we show here to 
contribute to ligand binding. Whereas the hydrophobic core in h/xeFn14 is very compact (Phe63/xPhe54 
and Met50/xMet41, surrounded by a small-amino acids garland: Ser41/xAla32, Ser43/xSer34, Ser54/xVal45 and 
Ser61/xSer52 , Fig. 3D), the hydrophobic core of TACI_d2, involves a number of bulkier hydrophobic 
residues including Phe78, Ile87, Ile92 and Pro97 [12] (Fig. 4C), causing a tertiary arrangement progressively 
more open in TACI_d2 and BCMA, (“opened-clamp” vs. “closed-clamp” in Fn14, Fig. 4).  
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As a functional consequence of the tertiary structure, BCMA and BAFFR engage BAFF (and APRIL) 
mostly through the β-hairpin interface [13, 21], with no fundamental contribution from residues in the C-
terminal helix-loop-helix region. The intermediate conformation in TACI_d2 involves a wider binding 
surface to APRIL, encompassing the concave face of the molecule (DXL hairpin plus residues in the 
helix-loop-helix motif) [12]. In the “closed-clamp” conformation seen in both human and xeFn14, the β-
hairpin and the helix-loop-helix motifs are in close proximity and define the binding epitope presented to 
TWEAK (Fig. 4). 
A discontinuous binding epitope: mutagenesis and molecular structure 
Previous studies have concluded that minimal ligand-induced structural changes occur when BAFFR, 
BCMA or TACI_d2 bind their respective ligands [11-13], an observation confirmed by the present 
solution structure of BCMA. A model of hFn14 bound to TWEAK was constructed based on the 
assumptions that a) the structure of free Fn14 and TWEAK-bound Fn14 is similar and b) the region 
contacted by Fn14 in TWEAK corresponds to that contacted by BAFFR, BCMA and TACI_d2 in BAFF 
and APRIL. We based our homology model on the available structure of the APRIL-TACI complex 
(PDB code 1XU1) [12]. Fn14 contacts TWEAK along a relatively narrow but elongated surface 
comprising, on one hand, the C-terminal end of the CD loop plus β-strand E of TWEAK, and, on the 
other hand, the β-hairpin and part of the C-terminal portion of Fn14 . 
The molecular model of the TWEAK-Fn14 complex, which takes into account the experimentally 
determined structure of Fn14, clearly highlights that residues belonging to the two lobes of Fn14 (the β-
hairpin and the helix-loop-helix domain) make determinant contributions to the binding interface. Based 
on the complex structure, selected point mutations were introduced in Fn14 and TWEAK in order to 
probe potential residues involved in the receptor-ligand interactions. Full-length forms of Fn14 were 
expressed in 293T cells and stained by FACS with Flag-TWEAK, or with a monoclonal anti-Fn14 
antibody (ITEM-4) to control expression levels (Fig. 5A). Leu46 was deemed important for binding and 
indeed upon mutation (L46A) binding affinity to TWEAK was reduced, while all other Fn14 mutants 
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tested bound Flag-TWEAK as efficiently as wild type Fn14 (Fig.  5B). Consequently we introduced a 
series of double mutations in the hFn14 sequence that combine a residue from the β-hairpin’s tip and a 
residue from the helix-loop helix, expressed them in 293T cells and tested them for binding to hTWEAK. 
Several double mutants resulted in partial or complete loss of binding to TWEAK: L46A/P59A, 
L46A/S61A, L46A/D62A and L46A/F63A (Fig 5C).  To confirm the importance of the SXDL motif a 
number of double mutants with both residues within the β-hairpin were also examined. Mutants 
S43A/L46A, D45A/L46A, D47A/L46A, K48A/L46A almost completely lost the ability to bind to 
TWEAK (Fig 5C).  
Similarly we mapped the TWEAK binding interface, revealing the importance of Tyr176 (Y176A 
completely abolishes binding; Fig. 5D), and the contribution of Lys178, Arg190 and Leu198 (K178A, R190A 
and L192E all failed to interact with Fn14 L46A, the weakened receptor for TWEAK; Fig. 5E). The 
residues thus discovered all appear to be involved in specific receptor-ligand interactions and are 
highlighted in figure 6. For example Leu46 on Fn14 interacts with Leu192 on TWEAK, Asp47-Fn14 at 
Lys235-TWEAK, Ser61/Asp62-Fn14 at Lys178-TWEAK. Pro59, which has a moderate effect on the binding 
affinity in the double mutant Fn14, may play a structural role or additionally directly participate in 
binding, similar to the corresponding residue Pro97 of TACI_d2 (part of the hydrophobic surface 
interacting with APRIL). We attribute a structural role also to Met50: as part of the hydrophobic core of 
Fn14 (only 20% of its surface is accessible) it is not predicted to contact TWEAK directly but rather to 
play a major role in determining the relative orientation of the N- and C-terminal lobes. A similar effect 
was reported previously for the equivalent position of TACI_d2 (Ile87) [12] (Fig. 4C). Several residues 
showed no contribution to binding (Fig. 5C): Arg56, Arg58 and Leu65 are pointing away from the TWEAK 
interface in the model and make no or little contacts with TWEAK while His60 points toward Glu194 and 
Phe195 of TWEAK.  
Within the series of single mutant hFn14 constructs, the result that each mutation taken alone did not 
disrupt (or only reduced, e.g. L46A) ligand binding indicates that none of these mutations resulted in 
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gross unfolding or intracellular retention of hFn14. It is noteworthy that our results are in contrast with a 
previous report indicating that the D62A mutation totally prevented the secretion of Fn14 protein and 
several single point mutations disrupted binding[22]. The secretion of soluble D62A mutant may be 
affected by the use of full length human Fn14 in this study, versus a murine sequence of the sole 
extracellular domain of Fn14 fused to murine Fc and a Myc tag. We also tested mutations in neighboring 
amino acids, S61A and F63A, which yielded Fn14 mutants able to bind TWEAK. In addition, the binding 
assay modalities were largely different:  binding affinities in this study were compared by FACS analysis 
on cells expressing the described Fn14 mutants with increasing Flag-TWEAK concentrations (upward of 
10 µg/ml), where the study reported in [22] measured binding affinity at two concentrations of purified 
receptors to TWEAK immobilized on a solid surface and the weakest detected binding was reported as a 
KD of 71nM. To confirm correct folding of the mutant proteins, a representative double mutant, 
hFn14(L46A, R58A),  was expressed and purified and examined by 1H, 15N-HSQC NMR. The protein 
spectrum (Fig. S2) closely tracks with the one of wild type hFn14, with chemical shifts perturbations 
corresponding only to the sites adjacent to the mutated residues as expected, indicating the wild type and 
mutant proteins are similarly folded.  
Taken together, our data indicate that the Fn14-TWEAK interaction involves elements from the β-hairpin 
as well as from the helix-loop-helix motif. The observation that single point mutations are well tolerated 
seems to indicate that the multiple sites of this non-contiguous interaction interface may contribute 
substantially to the energy of binding, which should be taken into account for the development of low 
molecular weight molecules aimed at modulating the TWEAK-Fn14 interaction. 
Fn14: the evolutionary perspective  
The TNF superfamilies of ligands and receptors have expanded considerably during evolution, from a 
single pair in drosophila (Eiger-Wengen) to more than twenty in human, as higher organisms relied more 
and more on these ligand/receptor interactions for controlling cell fate decisions. The evolutionary origin 
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and diversification of these pairs is however incompletely understood. In the current study, we describe 
that the interface between the TNF ligand TWEAK and its cognate receptor Fn14 has been conserved. 
Although it may seem remarkable that xenopus Fn14 cross-reacts with human TWEAK, inter-species 
cross reactivity is not uncommon in the TNF family: 72% of the TNF ligands and receptors cross-react 
between human and mouse [23], human BAFF binds to chicken BAFFR [24], chicken BAFF binds to 
human BCMA [25], and mammalian EDA is even active in fishes [26]. The strong structural similarity 
that we observe between human and xenopus Fn14 despite divergent primary sequences is probably due 
to the presence of a structural core stabilized by disulfide bonds, as shown previously for other protein 
families [27, 28]. 
Most TNF receptor family members, such as TNFR1, TNFR2 and Fas, contain three or four cystein-rich 
domains, usually composed of A and B modules (for a classification see [2]), suggesting that these 
receptors may have arisen by exon duplication of an ancestral cystein-rich domain such as that found in 
Wengen in the Drosophila [29] (Fig. 1B). The relatively recent identification of single CRD receptors in 
mammals raised the intriguing possibility that they could represent the ancestral molecules from which 
multi-CRD mammalian TNF receptors have evolved [12]. The TWEAK-Fn14 pathway may be one of the 
most ‘ancient’ from the perspective of evolution. Indeed, the other two single-CRD TNF receptors 
BAFFR and BCMA regulate B cell function in vertebrates only, whereas an Fn14-like sequence with 
perfectly conserved inter-cysteine spacing and exon-intron boundaries is found in the protochordate 
Branchiostoma floridae (Fig. 1A). This suggests that the origin of the TWEAK - Fn14 pathway preceded 
vertebrate evolution and the development of adaptive immunity. 
The structure of Fn14 allows formulating a hypothesis regarding the evolutionary relationship between 
modules differing in their patterns of disulfide bridges. Although the A1-C2 cysteine-bridging pattern that 
we describe in both human and xenopus Fn14 (the two C2 disulfides are nested) contrasts with the A1-D2 
pattern of BCMA and TACI (intercalated disulfides), we find that the three dimensional structure of Fn14 
could accommodate the A1-D2 disulfide pattern with only minor structural adjustments (Fig. 3C), 
suggesting that a certain level of ‘ambiguity’ in disulfide linkage formation may have existed in the 
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primordial single CRD TNF receptor, and that this flexibility may have accounted for the emergence of 
different modules found in mammalian TNF receptors. Similarly a swapping of disulfide paring has been 
reported to produce bioactive disulfide bond isomers of epidermal growth factor (EGF)-like domains 
[30]. 
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Materials and Methods 
Protein preparation   
Soluble Flag-tagged human TWEAK (Flag-hTWEAK) or Fc-hTWEAK (residues 106-249; a fusion 
protein between the Fc portion of human IgG1 and the TNF homology domain of hTWEAK) were 
generated and characterized as previously described [23]. Full length, untagged human Fn14 was cloned 
into the mammalian expression vector PCR3 (Life Technologies, Grand Island, NY, USA). Point 
mutations were introduced by conventional PCR-based methods in full-length Fn14 and hTWEAK, and 
the resulting plasmids were sequenced on both strands. His-tagged hTWEAK (His-hTWEAK, residues 
106-249) and the soluble ectodomains of human Fn14 (residues 28-80) and xenopus Fn14 (residues 23-
72) fused to Myc and His tags were cloned and expressed in Pichia pastoris according to protocols 
previously described [31]. The molecular weight of hFn14 as determined by MS spectrometry was 7617 
Da, matching the oxidized state for all six cysteine residues and no post-translational modification [10]. 
Uniformly 15N labeled hFn14 and xeFn14 for NMR studies were prepared from cultures supplemented 
with (15NH4)2SO4 following published procedures [32]. Additional forms of soluble Fn14 used in this 
study included Fc-hFn14 and Fc-xeFn14 (CHO or 293T mammalian cells). The L46A, R58A mutant of 
hFn14 was initially cloned in a pQE vector (Qiagen) and subject to PCR-based site directed mutagenesis 
to introduce A46 and A58. It was subsequently subcloned in a modified pET32b vector (Novagen, EMD 
Millipore, Billerica, MA, USA) between the BamHI and XhoI restriction sites, as a His6-thioredoxin 
fusion protein containing a tobacco etch virus (TEV) cleavage site and expressed and purified from E. 
Coli BL21 Star (DE3) (Life Technologies) as in [33]. The last purification step of the cleaved 
hFn14(L46A,R58A) consisted in size exclusion chromatography (GE Healthcare Biosciences, Pittsburgh, 
PA, USA, Superdex Peptide 10/300GL), were the protein eluted at the expected mass for a monomeric 
species. The protein was characterized by SDS-PAGE and 1H,15N NMR spectroscopy. 
The cysteine-rich domain of human BCMA (2-50) was synthesized by solid phase peptide synthesis 
(supplementary material).ELISA Assay 
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Microtiter plates were coated with hFn14 or xeFn14 at 10 µg/ml in 100 mM Na-Carbonate buffer, pH 9.2, 
and then blocked with ELISA buffer (phosphate buffered saline - PBS: 10 mM phosphate, 137 mM NaCl, 
2.7 mM KCl, pH 7.4 - 5% non-fat dry milk, 0.05% Tween-20). Plates were washed with wash buffer 
(PBS, 0.05% Tween-20) and the indicated concentrations of Fc-hTWEAK in ELISA buffer were added 
for 1 h at room temperature. Plates were washed and bound Fc-hTWEAK was detected by adding 
horseradish peroxidase-labeled goat anti-human IgG (Fc specific) (Jackson ImmunoResearch 
Laboratories, Inc., West Grove, PA, USA) at a dilution of 1:1000 in ELISA buffer for 1 hour at room 
temperature. Plates were developed with TMB substrate (Pierce, Rockford, IL, USA), the reaction was 
stopped by addition of 2 N H2SO4 and absorbance was read at 450 nm. EC50 values were determined from 
an empirical 4-parameter fit to the data: 
y = (a((bx)c)/(1+((bx)c)))+d 
where:  a = upper asymptote 
b = midpoint (EC50) 
c = slope of linear part of curve 
d = lower asymptote 
Cell surface binding analysis  
 293T cells were transiently transfected by the calcium phosphate precipitation method with plasmids 
containing full-length wild type human or xeFn14 cDNAs, together with an EGFP expression plasmid 
[34]. Cells were harvested 24 hours post transfection and stained with varying amounts of Fc-hTWEAK, 
followed by FITC- or PE-conjugated goat anti-human Fc secondary antibodies. This allowed semi-
quantitative estimation of apparent KD’s of binding between Fc-hTWEAK and hFn14 or xeFn14 
expressed on the cell surface. Alternatively, 293T cells were co-transfected by the calcium phosphate 
method with plasmids encoding EGFP and human Fn14 (wild type, or with the indicated single or double 
mutations). Cells were stained 48 h post-transfection with 50 µl of Flag-hTWEAK (wild type or mutants) 
at the indicated concentrations, followed by biotinylated anti-Flag M2 antibody (Sigma-Aldrich, St. 
Louis, MO, USA) and PE-coupled streptavidin. Cells were also stained with biotinylated ITEM-4 (anti-
Fn14 monoclonal antibody), followed by PE-coupled streptavidin. The mean fluorescence intensity of 
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Flag-hTWEAK staining was measured on cells expressing intermediate levels of EGFP (fluorescence 
intensity of 100-1000) and was normalized to the level of Fn14 expression measured with ITEM-4. 
Surface Plasmon Resonance Assay 
All Experiments were performed using a Biacore 3000 instrument (GE Healthcare). His-hTWEAK [16] 
was immobilized on a CM5 sensorchip as described [35]. Soluble, monomeric human or xenopus Fn14 
was diluted in Biacore assay buffer (Biacore buffer + 0.05% BSA) to the indicated concentrations and 
injected over the TWEAK derivatized or control surface, at a flow rate of 50 μl/min. The TWEAK 
surface was regenerated with 2 x 30 s injections of 10 mM H3PO4. In all cases binding to the 
underivatized chip was negligible. Affinity was determined by fitting plots of the response value where 
binding has come to equilibrium (Req) versus concentration to a hyperbolic single-site binding equation 
[28].    
NF-kB luciferase assay 
293T cells were plated at 104 cells/well in 96 well plates in 100 µl DMEM supplemented with 10% FCS. 
Two days later, plasmid mixes were prepared in one volume DMEM without supplement, mixed with 
0.07 volume of Polyfect (Qiagen) for 5 min, diluted with 5 volumes of DMEM, 10% FCS and distributed 
(25 µl) on cells in 50 µl fresh complete medium. Each well received hFn14 or xeFn14 plasmids (20 ng 
and 3-fold dilutions), ± 4 ng of huTWEAK plasmid and with 7.5 ng each of NF-κB firefly luciferase, 
renilla luciferase an EGFP plasmids, with empty vector to get 70 ng of plasmid per well. After 48 h, cells 
were washed, lysed and assayed for firefly and renilla luciferase using a dual reporter luciferase assay 
(Promega). Firefly luciferase activity was normalized to that of renilla luciferase. NF-kB activation was 
expressed as fold increase relative to signals obtained in cells transfected without Fn14.  
NMR Spectroscopy 
NMR samples typically consisted of 500-700 µM 15N-xeFn14, 15N-hFn14 or hFn14, in PBS (pH 7.4), 5% 
D2O. 900 µM BCMA was dissolved in 10 mM phosphate buffer, pH 6.0, 0.02% NaN3, 5% D2O. NMR 
spectra were acquired on a Bruker Avance 600 spectrometer equipped with a triple resonance CryoProbe 
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or TXI probe, at 10-45°C. 1H and 15N assignments were obtained using three-dimensional 15N-edited 
NOESY-HSQC (100ms) and TOCSY-HSQC experiments [36] (64, 200 and 1024 complex points in the 
15N and 1H dimensions) and  two-dimensional homonuclear experiments: TOCSY, NOESY (90ms), 
double quantum filtered-COSY [37]. All NMR data were processed using TOPSPIN (version 1.3, Bruker-
Biospin) and analyzed using Sparky [38]. 
Structure Calculation  
Complete proton and nitrogen resonances assignment was obtained following previously described 
procedures [39].   Distance restraints were derived from the 3D 1H-15N edited NOESY and 2D 1H-1H 
NOESY experiments, with mixing times varying between 80 and 100 ms.  For each protein, 100 
structures were calculated using the torsion angle simulated annealing protocol of CNX (version 2002, 
Accelrys Inc., San Diego, CA, USA) using standard parameters [40], and the 20 structures with lowest 
total energy were chosen for analysis.  The residues in the Myc-His tag were excluded from the structure 
calculation. The quality of the structures was analyzed using VADAR [41] , and the experimental NMR 
restraints were quantitatively evaluated using QUEEN [20] (calculation of the unique information, Iuni, 
and average information content sampled throughout the complete dataset, Iave, over 25 iterations, of each 
restraint). The structures were visualized with Chimera [42].  
Disulfide bond determination  
Disulfide-bond assignments for all three structures were confirmed by NMR utilizing to the method of 
Klaus et al. [43], which determines the most likely pattern of disulfide bonds based on the calculation of 
all possible distances between Cβ of cysteine residues involved in disulfide bonds within the initial family 
of NMR structures (calculated in absence of explicit S-S bonds definitions). To investigate the 
consequences of disulfide swapping a set of structures with the alternative disulfide configuration was 
calculated as well. 
 Molecular Modeling of TWEAK-Fn14 Interactions  
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The model of TWEAK was generated by template forcing homologous sequence regions (as generated by 
BLAST [44]) to the three-dimensional structure of APRIL (PDB entry 1XU1) [12] with InsightII 
(Accelrys). The model of the TWEAK trimer and the structure of Fn14 were superimposed respectively 
on the crystal structure of APRIL and the bound second CRD domain of TACI (TACI_d2) (PDB entry 
1XU1) [12] using InsightII. The complex was then subjected to extensive energy minimization (steepest 
descents followed by the quasi-Newton-Raphson method, VA09a until the derivatives were less than 0.5 
kcal/mol Å, CVFF91 forcefield ), first with the NMR distance constraints applied  to maintain the Fn14 
structure (force constant of 100 kcal mol-1 Å-2), and then again with no constraints, allowing the complex 
to relax.  
 17 
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Figure S1: 2D NOESY spectra of hFn14 and xeFn14. Figure S2: 1H,15N HSQC spectra of hFn14(28-
80) and hFn14(L46A,R58A). Methods for the synthesis of BCMA. 
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 Table 1. Restraints and statistics for the ensemble of 20 structures of hFn14, xeFn14 and BCMA 
 hFn14 xeFn14 BCMA 
NOE restraints 230 218 279 
intraresidue 79 56 78 
sequential 89 81 100 
medium range 1 < |i − j| < 5 28 31 45 
long range |i − j| ≥ 5 34 50 56 
Rms deviation from experiment    
NOE constraints (Å) 0.015 0.035 0.060 
Rms deviation from idealized geometry    
bonds (Å)  0.002 0.003 0.005 
angles (deg)  0.3 0.4 0.7 
Ramachandran analysisa     
most favored regions (%)  56.3±6.7 61.2±5.0 56.0±4.5 
additionally allowed regions (%)  34.2±5.7 34.0±5.9 30.8±4.5 
generously allowed regions (%)  5.8±3.4 3.1±2.3 8.9±2.4 
disallowed regions (%)  0.2±0.7 0.1±0.4 0.2±0.6 
Average pairwise rms deviations (Å)    
Ser40/xPro31 to Cys67/xCys58  0.747 0.760  
a VADAR was used to assess the stereochemical quality of the structures 
 21 
Figure Legends 
Figure  1. Sequence alignment of Fn14 and other small TNF receptors. A: Sequence alignment of Fn14 
from human (Homo sapiens), mouse (Mus musculus), frog (Xenopus laevis), fish (Gasterosteus 
aculeatus) and a protochordate (Branchiostoma floridae). Conserved residues in the extracellular domain 
are shaded.  Numbering corresponds to the human sequence. TMD: transmembrane domain. TRAF: 
consensus TRAF binding site. Exon boundaries, when known, are indicated. B: Sequence alignment of  
the central portion of the extracellular domains of single-CRD TNF receptors and of TNFR1. The 
elements of secondary structure (β-sheets in green, α-helices in red) are indicated, as well as the disulfide 
bonds. Residues on purple background were experimentally shown to participate in ligand binding (for 
Fn14, BCMA, TACI and BAFFR) or to contact the ligand in the ligand-receptor complex (TNFR1). The 
module composition of the CRD is shown on the right. dWengen: Drosophila Wengen. 
 
Figure 2. Cross-species binding of Fn14 to human TWEAK.  A: 293 T cells were transiently transfected 
with the indicated amount of plasmids encoding full-length hFn14 or xeFn14, stained with Fc-hTWEAK 
at the indicated concentrations, and analyzed by FACS. MFI: mean fluorescence intensity. B: ELISA 
assay. Immobilized hFn14 and xeFn14 binding to Fc-hTWEAK and detected with anti-human Fc 
secondary reagents. A 4-parameter equation fitting yielded an apparent EC50 of 0.3 nM. C, D: The binding 
of monomeric Fn14 (in solution) to immobilized trimeric His-hTWEAK on a Biacore chip. The plot of 
the signal achieved at equilibrium (Req) as a function of the xeFn14 (C) or hFn14 (D) concentration was 
fitted to a single site binding model as described in Materials and Methods. E: Induction of NF-κB-
luciferase reporter activity in 293T cells transfected with varying amounts of xeFn14 or hFn14 plasmids, 
in the presence or absence of a fixed amount of co-transfected TWEAK. NF-κB activity is expressed as a 
fold increase relative to cells transfected without Fn14.  
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Figure 3. NMR solution structure of human and xenopus Fn14. A: Superposition of 20 low energy NMR-
derived structures of hFn14 (backbone atoms 36-67). The three disulfide bridges are shown in yellow 
ball-and-sticks for one of the structures. The boundaries of the A1 and C2 structural modules are 
indicated by brackets. B: Superposition of low energy structures of hFn14 (gray) and xeFn14 (brick), 
displayed as ribbons. Residues 36, 40-52 and 61-64 of hFn14 and corresponding residues of xeFn14 were 
used in the superposition. C: Top view of hFn14 with cysteines highlighted in yellow ball-and-sticks. The 
arrows indicate changes in disulfide connectivity that would be required to swap from nested to 
intercalated disulfide bridges in the C2 module. D: The hydrophobic core of hFn14 is constituted of Phe63 
and Met50 (carbon atoms in green), and is surrounded by small amino acids (Ser41, Ser43, Ser54 and Ser61, 
carbon atoms in sky blue). Protons are colored white, oxygens red and sulfur yellow. 
 
Figure 4. Comparison of the structural features of hFn14 with BCMA, TACI_d2 and BAFFR. Selected 
residues are displayed as sticks: in green, residues in the hydrophobic core; in blue, residues relevant for 
binding in the β-hairpin and helix2. The conserved aromatic is shown in sky blue and disulfides bridges in 
yellow. Corresponding residues are displayed in the same coloring scheme in panels A-D. A: NMR 
structure of hFn14.  B: NMR structure of hBCMA determined in this study. Tyr13 that fulfills a similar 
structural role as Fn14’s Phe63 is shown. C: NMR structure of hTACI_d2 (PDB code 1XUT). D: Crystal 
structure of hBAFFR (PDB code 1OQE).  Structures shown in panels A to D were first superimposed on 
their β-hairpins. Note that the N- and C-terminal domains adopt different relative orientations in Fn14 
than in BCMA and TACI_d2, which may allow engagement of different epitopes in ligand binding. 
 
Figure 5. Mutagenesis of Fn14 and TWEAK. A: The indicated full-length forms of wild type or mutant 
Fn14 were expressed in 293T cells and stained by FACS with Flag-TWEAK at the indicated 
concentrations (for Flag-TWEAK, 1 µg/ml corresponds to 50 nM), or with a monoclonal anti-Fn14 
antibody (ITEM-4) as an expression control. B: The binding of wild type TWEAK to wild type and 
 23 
mutant Fn14 was monitored as shown in panel A. The mean fluorescence intensity of TWEAK binding 
on cells expressing 102 – 103 fluorescence units of EGFP (rectangle shown in the first scattergram of 
panel A) was normalized to the staining intensity obtained with ITEM-4, and plotted as a function of 
TWEAK concentration. C: Same as panel B, except that the Fn14 mutations were combined with the 
L46A mutation. D: 293 T cells transfected with full-length wild type Fn14 were stained with the indicated 
concentration of Flag-TWEAK with the indicated mutations. Only TWEAK mutation Y176A abolished 
binding to Fn14.  E: Same as panel D, but with Fn14 mutant L46A. The TWEAK mutants K178A, 
R190A and L192E all failed to interact with Fn14 L46A, which displays a weaker affinity for TWEAK.  
 
Figure 6. Molecular model of the TWEAK-Fn14 complex. A: Residues of hFn14 that were tested in the 
mutagenesis study. Residues shown in red were critical for ligand binding (in combination with mutation 
L46A), the residue shown in orange decreased binding, and residues shown in green had no or little effect 
on ligand binding when mutated to alanine. Residues marked with an asterisk are within 4 Å of TWEAK 
in the model. Note that residues important for binding are located in both the A1 and C2 modules. B: 
Model of hFn14 binding to hTWEAK. Residues of both Fn14 and TWEAK that are likely to participate 
directly in the interaction and whose mutation affects the binding are highlighted (in sticks, green: 
hydrophobic, red: acidic, blue: basic). The TWEAK trimer is represented in ribbons in shades of gold. 
Fn14 is in gray ribbon. Fn14 in panels A and B appears rotated approximately 180 degrees, to allow for 























































































































































































































































































































































































































































































































































































































































Exon boundaries in fishes
Exon boundaries in protochordate
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 32  GTAPCSRG—-SSWSADLDKCMDC-ASCRARPHSDFCL-GCAAAPPAPF  75
 23  SQGECPEG—-RAYSQDLGKCMEC-SVCKNSEKSDFCQ-NCPSKTEQPD  66
167     TCHAG——-FFLRENECVSCS-NCKKS—-LECTKLCLPQIENVK 203
 4  MAGQCSQN—-EYFDSLLHACIPCQLRCSSNTPPLTCQRYCNASVTNSV  49
 69    LSCRKE-QGKFYDHLLRDCISCASICGQHP—KQCAYFCENKLRSPV 111
 15  APTPCVPA—-ECFDLLVRHCVACGLLRTPRPKPAGASSPAPRTALQPQ  60
126     GCRKNQYRHYWSENLFQCFNCS-LCLNG—-TVHLSCQEKQNTVCT  167
 82    RECES-GSFTASENHLRHCLSCS-KCRKEMGQVEISSCTVDRDTVCG  126
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